The result for bosentan is intriguing as many of the detrimental actions of ET-1, particularly in cancer, may use the β-arrestin pathway, and this suggests the potential to block a deleterious pathway while preserving activation of a beneficial pathway. Here, EDN1 is linked to cancer.